BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.

Gary M MiddletonYiqun YangCatarina D CampbellThierry AndréChloe E AtreyaJan H M SchellensTakayuki YoshinoJohanna C BendellAntoine HollebecqueAutumn J McReeSalvatore SienaMichael S GordonJosep TaberneroRona YaegerPeter J O'DwyerFilip De VosEric Van CutsemJohn M MillhollandJan C BraseFatima RangwalaEduard GasalRyan B Corcoran

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

BM subtype is significantly associated with the outcome of combination dabrafenib, trametinib, and panitumumab therapy and may serve as a standalone predictive biomarker beyond mutational status. Our findings support a more nuanced approach to targeted therapeutic decisions that incorporates assessment of transcriptional context.

Keyphrases

wild type
metastatic colorectal cancer
gene expression
small cell lung cancer
transcription factor
epidermal growth factor receptor
tyrosine kinase
heat shock
cancer therapy
mesenchymal stem cells
pi k akt
signaling pathway
combination therapy